Can Antihistamines Cause Fatty Liver?

Can antihistamines cause fatty liver disease? This is a question that understandably concerns people who take these widely used medicines for conditions such as hay fever, urticaria, or allergic rhinitis. The short answer is that there is no established causal link between standard antihistamine use and fatty liver disease. However, some antihistamines, particularly older first-generation agents, have been associated with rare liver enzyme elevations and drug-induced liver injury. This article explains what the evidence shows, which antihistamines carry the greatest risk, who is most vulnerable, and what to do if you have concerns about your liver health.

Can antihistamines cause fatty liver disease?

Antihistamines are not a recognised cause of fatty liver disease; the condition is primarily driven by metabolic factors. Some first-generation agents have been rarely linked to drug-induced liver injury, which is a distinct condition.

There is no established, direct causal link between standard antihistamine use and the development of fatty liver disease (hepatic steatosis) in the general population. Fatty liver disease is primarily driven by factors such as excess body weight, type 2 diabetes, high alcohol intake, and metabolic syndrome, rather than by antihistamine use alone. That said, some antihistamines, particularly older first-generation agents, have been associated with liver enzyme elevations and, in rare cases, drug-induced liver injury (DILI), which is a distinct condition from fatty liver disease.

It is worth understanding the difference between these two conditions. Fatty liver disease (also referred to in UK clinical guidance, including NICE NG49, as non-alcoholic fatty liver disease or NAFLD) involves the accumulation of fat within liver cells and is largely a metabolic disorder.^[1] Drug-induced liver injury, by contrast, refers to liver damage triggered by a medication's direct toxic effect or an immune-mediated reaction. While antihistamines are not a recognised cause of fatty liver disease, some preclinical research has explored whether histamine receptor signalling may play a role in hepatic lipid metabolism. These findings are preliminary, have not been consistently replicated in human studies, and should not be interpreted as evidence that antihistamines cause fatty liver disease in clinical practice.

This article focuses on H1 antihistamines used for allergic conditions (such as hay fever, urticaria, and allergic rhinitis). H2 receptor antagonists, which are used for acid-related conditions and are a separate drug class, are not discussed here.

For most people taking antihistamines at recommended doses for short periods, the risk of any significant liver-related harm is considered low. However, individuals with pre-existing liver conditions, those taking multiple medications, or those using antihistamines beyond the recommended dose or duration should discuss this with their GP or pharmacist. If you have concerns about your liver health while taking any medication, speaking to your GP is the appropriate first step.

What does the current evidence say about antihistamines and liver health?

Current evidence does not support antihistamines as a significant independent cause of fatty liver disease. Preclinical findings on histamine receptors and hepatic lipid metabolism have not been consistently replicated in human trials.

The current evidence on antihistamines and liver health is limited and largely observational, meaning a definitive causal relationship has not been established. Some preclinical studies have suggested that histamine receptors, particularly H1 and H2 subtypes, may be involved in regulating lipid metabolism in the liver.^[2][3] Animal studies have indicated that blocking these receptors could, under certain experimental conditions, promote fat accumulation in liver tissue.^[3][4] However, these findings have not been consistently replicated in robust human clinical trials, the mechanisms are not fully understood, and the clinical significance in people taking standard antihistamine doses remains uncertain. These preclinical observations should not be taken as evidence of a direct risk in humans.

A small number of observational studies have noted associations between long-term antihistamine use and markers of metabolic dysfunction, including elevated liver enzymes or increased body weight. Observational associations of this kind do not establish causality, and confounding factors (such as the underlying conditions being treated) may explain the findings. Weight gain is listed as a possible side effect in the prescribing information for certain first-generation antihistamines, and weight gain over time is itself a recognised risk factor for NAFLD.^[5][7] This indirect pathway, via weight gain, is considered more plausible than a direct hepatotoxic mechanism for most antihistamines.

The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) monitor post-marketing safety data for all licensed medicines, including antihistamines. Liver-related adverse events are listed in the prescribing information (available via the electronic Medicines Compendium, emc) for certain antihistamines, but these are generally categorised as rare. The overall evidence base does not support the conclusion that antihistamines are a significant independent cause of fatty liver disease, though research into the role of histamine signalling in hepatic lipid metabolism is ongoing.

Which antihistamines carry the greatest risk of liver-related side effects?

First-generation antihistamines, including chlorphenamine, promethazine, and cyproheptadine, have the most documented liver-related adverse effect reports. Serious hepatotoxicity remains rare across all antihistamine classes.

Published case reports and post-marketing surveillance data suggest that first-generation antihistamines have more documented reports of liver-related adverse effects than newer second-generation agents, though serious hepatotoxicity remains rare across the class as a whole. Agents such as chlorphenamine, promethazine, and cyproheptadine have been associated with isolated reports of liver enzyme elevations and, very rarely, cholestatic hepatitis (a pattern of liver injury affecting bile flow).^[7][12] Cyproheptadine is also associated with appetite stimulation and weight gain in its prescribing information, which may indirectly affect liver health over time.^[5][6] Readers should note that cyproheptadine has a limited range of licensed indications in the UK; if you are unsure whether it is appropriate for you, check with your GP or pharmacist.

Among second-generation antihistamines, cetirizine and loratadine are widely used and generally considered to have a favourable liver safety profile. However, rare cases of drug-induced liver injury have been reported with cetirizine in post-marketing surveillance, and loratadine has similarly been associated with very infrequent reports of hepatic reactions.^[9][7] These are isolated case reports rather than evidence of a systematic risk, and the absolute incidence remains very low. For specific hepatic adverse effect frequencies and any dosing advice in liver disease, refer to the relevant SmPC on the electronic Medicines Compendium (emc) at medicines.org.uk.

The following factors may increase the likelihood of liver-related effects with any antihistamine:

• High doses or prolonged use beyond the recommended duration

• Concurrent use of other medicines that can affect the liver, including paracetamol above the recommended dose, or certain antibiotics

• Combination products (such as some cold and flu remedies) that contain both an antihistamine and paracetamol, which can make it easier to exceed the recommended paracetamol dose inadvertently

• Pre-existing liver disease, which may impair drug metabolism

• Regular alcohol consumption, which places additional strain on the liver and can increase sedation with first-generation antihistamines

Always read the patient information leaflet supplied with your antihistamine and follow the recommended dosing instructions. If you are taking any antihistamine regularly for more than a few weeks, discuss this with your GP or pharmacist to ensure it remains appropriate for your circumstances.

Who is most at risk, and what symptoms should you watch for?

People with pre-existing liver disease, older adults, and those with metabolic syndrome or polypharmacy are most at risk. Symptoms such as jaundice, dark urine, or upper right abdominal pain should prompt prompt medical review.

People with pre-existing liver conditions, including NAFLD, alcoholic liver disease, or hepatitis, are most at risk of experiencing liver-related complications when taking antihistamines, because their liver's capacity to metabolise drugs may already be reduced. Similarly, older adults, people taking multiple medications (polypharmacy), and those with type 2 diabetes or obesity face a higher background risk of liver dysfunction, which may be compounded by any additional hepatic stress from medication.

Individuals who consume alcohol regularly should be particularly cautious with first-generation antihistamines, as alcohol and these agents can interact to increase sedation and place additional burden on the liver.^[12] People with known metabolic syndrome, characterised by a combination of central obesity, raised blood pressure, elevated blood glucose, and abnormal lipid levels, already have a heightened risk of fatty liver disease, and any additional metabolic effects from long-term antihistamine use may be relevant in this group.

Symptoms that may suggest liver involvement and should prompt medical review include:

• Persistent fatigue or unexplained tiredness

• Yellowing of the skin or whites of the eyes (jaundice)

• Dark urine or pale stools

• Upper right abdominal discomfort or pain

• Nausea, loss of appetite, or unexplained weight loss

• Itching of the skin without an obvious cause

These symptoms are not specific to antihistamine use and can have many causes. If you notice any of them while taking an antihistamine, the appropriate action depends on the medicine:

• If you are taking an over-the-counter antihistamine, stop taking it and contact your GP promptly, or call NHS 111 for advice.

• If you are taking a prescribed antihistamine, do not stop it without medical advice; contact your prescriber the same day.

New-onset jaundice or severe abdominal pain warrants same-day assessment. Contact your GP urgently, call NHS 111, or go to an urgent care centre. If you feel severely unwell or have additional symptoms such as confusion or collapse, go to your nearest A&E or call 999.

What should you do if you are concerned about your liver while taking antihistamines?

Speak to your GP, who can arrange liver function blood tests and review your medications. Jaundice or severe abdominal pain requires same-day assessment; suspected side effects should be reported via the MHRA Yellow Card scheme.

If you are concerned about your liver health while taking antihistamines, the most appropriate first step is to speak to your GP. Your GP can arrange blood tests to assess liver function, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), bilirubin, and albumin.^[11] For people with suspected NAFLD, NICE guideline NG49 recommends using a risk stratification tool such as the FIB-4 score to guide further investigation and referral. The British Society of Gastroenterology (BSG) also provides guidance on the investigation and referral of people with abnormal liver blood tests.^[11] Your GP can review your full medication list to identify any potential interactions or cumulative hepatic burden, and advise whether continuing, switching, or stopping the antihistamine is appropriate.

For most people using antihistamines at standard doses for short-term symptom relief, such as seasonal hay fever, no specific liver monitoring is required. However, if you are using an antihistamine long-term, particularly a first-generation agent, or if you have a known liver condition, your GP may recommend periodic liver function testing as a precaution.

If you develop jaundice or severe abdominal pain while taking an antihistamine, seek same-day medical assessment as described in the section above. If you are taking an over-the-counter antihistamine and suspect it may be causing a liver reaction, stop taking it and seek urgent advice. If you are taking a prescribed antihistamine, contact your prescriber urgently the same day rather than stopping it without guidance.

If you believe you have experienced a side effect from an antihistamine, including any liver-related symptom, you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. This reporting system helps the MHRA monitor the safety of all medicines used in the UK, including those available over the counter.

More broadly, supporting liver health involves addressing modifiable risk factors: maintaining a healthy body weight, limiting alcohol intake within recommended guidelines, eating a balanced diet, and managing conditions such as type 2 diabetes and high cholesterol with appropriate medical support. These lifestyle measures remain the cornerstone of preventing and managing fatty liver disease, regardless of antihistamine use.

Scientific References

1. Metabolic dysfunction-associated steatotic liver disease (NG49).
2. Histamine regulation in glucose and lipid metabolism via histamine receptors.
3. H1-antihistamines exacerbate high-fat diet-induced hepatic steatosis.
4. Novel function of histamine signaling via histamine receptors in cholesterol and bile acid metabolism: Histamine H2 receptor protects against nonalcoholic fatty liver disease.
5. Cyproheptadine hydrochloride | Drugs - BNF - NICE.
6. Use of cyproheptadine to stimulate appetite and body weight gain.
7. Home - electronic medicines compendium (emc).
8. Subfulminant liver failure and severe hepatotoxicity caused by loratadine use.
9. A case of levocetirizine-induced liver injury.
10. The Yellow Card scheme: guidance for healthcare professionals, patients and the public.
11. Guidelines on the management of abnormal liver blood tests (BSG).
12. Comparative safety of H1 antihistamines.

Frequently Asked Questions